Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

M ultiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...

Multiple myeloma is the second most common type of blood cancer after leukemia. Learn more about the symptoms, causes, diagnosis, risk factors, and treatment of multiple myeloma.

Multiple myeloma is a cancer of your bone marrow. Specifically, it affects your plasma cells, which are white blood cells that make antibodies to fight germs and prevent infection and disease ...

Multiple myeloma is a rare blood cancer that is not hereditary. However, a family history of the disease may increase your risk of developing it.